Please login to the form below
Biosimilars - the Brexit of the pharmaceutical industry?
In this article, Senior Consultant Jenna Earl explains what factors influence the uptake of biosimilars in the UK, comparing them to the same principles that help us navigate the complexities of Britain exiting the EU (Brexit).
Despite
availability of biosimilars for nearly a decade, uptake in the UK is still
lagging behind other EU markets, leading to the recent formation of the British Biosimilars Association (BBA) - part of the British Generic Manufacturers Association (BGMA).
Biosimilars
are undoubtedly a hot topic for providers of branded biologic medicines,
biosimilar suppliers themselves, and the payers, healthcare professionals and
patients involved in biologic treatment. Much like the EU referendum, they
feature regularly in the news - with spectators waiting anxiously, in some
cases eagerly, for a change that could alter the treatment landscape for
several significant therapy areas.
To
understand the factors influencing the uptake of biosimilars you could apply
the same principles as you would to navigating the complexities of Britain
exiting the EU (Brexit).
Read the full article on the Blue Latitude Health blog
1. Control is in the hands of the people
Britain's relationship with the EU will be decided by a referendum, placing the decision in the hands of the people. In the UK, the decision to prescribe a biosimilar is still largely down to the healthcare professional (HCP) but, if this were to change, impact on biologic markets could be dramatic. Despite NICE recommending biosimilars ahead of branded biologics in several disease areas, this does not appear to be happening in clinical practice. The next step for governing bodies to ensure biosimilars are prioritised in the treatment pathway is substitution, replacing a branded biologic with its corresponding biosimilar at point of dispensing; a move that would result in a huge uplift in biosimilar use. Arguably, the reason this hasn’t happened yet is that the financial gain generated by such a move does not yet outweigh the repercussions of reducing the role of the HCP in such an important decision. But with increasing pressure on the NHS to make cost savings and expect greater value from treatments, this could change in the future.Read the full article on the Blue Latitude Health blog
Company Details
Blue Latitude Health
+44 203 328 1840
Address:
Blue Latitude Health (UK)
140 Aldersgate Street
London
EC1A 4HY
United Kingdom
Latest content on this profile
- Three strategies for managing loss of exclusivity successfully
- Consultant, Claire Taylor explains why you should be strategically planning your LOE strategy years in advance.
Blue Latitude Health
- What does the future hold for Medical Affairs?
- Lori Lush, Head of Fishawack Medical, reveals why she’s driven to tell impactful scientific stories, the benefits of cross-functional collaboration, and the trends she predicts for the next five years.
Blue Latitude Health
- Mistrust in medical research: a patient perspective
- The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the life sciences industry can do to rebuild trust.
Blue Latitude Health
- Real-world evidence: breaking boundaries in rare disease
- Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and Senior Consultant Craig Moore explore the benefits of using real-world evidence and the common pitfalls life science companies should avoid.
Blue Latitude Health
- The heavy toll of COVID-19 on cancer patients
- We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of this lost time for patients?
Blue Latitude Health
- Unpacking rare diseases in the first edition of Delta magazine
- Fishawack Health launches Delta magazine with a deep dive into rare disease commercialization
Blue Latitude Health
